1 Department of Radiology, Eastern Virginia Medical School, 600 Gresham Dr, Norfolk, VA 23510.
2 Dorothy G. Hoefer Comprehensive Breast Cancer Center, Newport News, VA.
AJR Am J Roentgenol. 2019 Mar;212(3):696-705. doi: 10.2214/AJR.17.18930. Epub 2019 Jan 8.
The purpose of this retrospective study was to evaluate the diagnostic performance of breast-specific gamma imaging (BSGI) and breast MRI in assessing for residual tumor after neoadjuvant chemotherapy (NAC) in patients with breast cancer.
A total of 114 patients underwent BSGI and MRI for initial staging as well as after undergoing NAC. Of those, 112 underwent subsequent definitive breast surgery. Thirty of the 114 patients had a complete pathologic response to NAC.
BSGI and MRI had comparable sensitivities in detecting residual tumor after NAC (70% vs 83%). BSGI had a higher specificity than MRI in accurately determining complete response after NAC (90% vs 60%).
BSGI may be a useful adjunctive tool for predicting a complete pathologic response to NAC.
本回顾性研究旨在评估乳腺癌患者新辅助化疗（NAC）后评估残留肿瘤的乳腺特异性伽玛成像（BSGI）和乳腺 MRI 的诊断性能。
共有 114 例患者接受了 BSGI 和 MRI 进行初始分期以及 NAC 后评估。其中 112 例患者随后进行了确定性乳房手术。114 例患者中有 30 例对 NAC 有完全病理反应。
BSGI 和 MRI 在检测 NAC 后残留肿瘤方面具有相当的敏感性（70%比 83%）。BSGI 在准确判断 NAC 后的完全缓解方面比 MRI 具有更高的特异性（90%比 60%）。
BSGI 可能是预测 NAC 完全病理反应的有用辅助工具。
